{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:36:06Z","timestamp":1762018566704,"version":"3.32.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Cancer-associated thrombosis (CAT) can increase morbidity and mortality for cancer patients. Therefore, guidelines recommend predicting VTE risk and thromboprophylaxis for high-risk patients. Many studies critique oncologists\u2019 adherence to thromboprophylaxis guidelines for cancer patients. Meanwhile, most of these studies did not discuss in detail the reasons and facilitators for oncologists\u2019 adherence to thromboprophylaxis guidelines. Therefore, the current study aimed to explore in depth the perceptions and practices of oncologists working in oncology centers in Baghdad, Iraq, regarding VTE and its risk assessment among ambulatory cancer patients. A qualitative study with face-to-face individual-based interviews was conducted with oncologists working in four major oncology centers in Baghdad, Iraq using a semi-structured interview guide. The guide was developed based on previous relevant literature and validated by a panel of experts. The interviews were conducted from November 2023 to January 2024. Thematic analysis approach was used for data analysis. Thirty-one oncologists were interviewed in this study. Twenty-two of the interviewed oncologists reported that they detect VTE among their cancer patients. 64% of participating oncologists reported that they did not conduct VTE risk assessments for their cancer patients. Only four oncologists reported assessing VTE risk using the Khorana score. 58% of oncologists reported that they prescribe thromboprophylaxis for high-risk patients; meanwhile, only 11% of them reported prescribing anticoagulants in a dose similar to that reported by thromboprophylaxis guidelines. 77% of participating oncologists reported that pharmacists have a significant role in preventing cancer-related thrombosis by helping physicians prescribe a safe and effective prophylactic anticoagulant and in calculating VTE risk scores. In conclusion, CAT is commonly diagnosed among Iraqi cancer patients. VTE risk assessment for ambulatory cancer patients is rarely conducted by oncologists working at Oncology centers in Baghdad, Iraq. The prophylactic anticoagulants were rarely prescribed in appropriate dose and\/or duration for patients at high risk of VTE. Pharmacists can help oncologists follow thromboprophylaxis guidelines by calculating VTE risk score and recommending a safe and effective dose of appropriate prophylactic anticoagulant.Educating and training oncologists about VTE risk assessment is recommended to enhance their practice in thromboprophlaxis.<\/jats:p>","DOI":"10.1371\/journal.pone.0316801","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T18:26:56Z","timestamp":1736188016000},"page":"e0316801","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Determining the perceptions and practices of oncologists regarding venous thromboembolism risk assessment in ambulatory cancer patients: A qualitative study"],"prefix":"10.1371","volume":"20","author":[{"given":"Marwa Akram","family":"Tariq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-4978","authenticated-orcid":true,"given":"Ehab Mudher","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"2","key":"pone.0316801.ref001","doi-asserted-by":"crossref","first-page":"e024805","DOI":"10.1136\/bmjopen-2018-024805","article-title":"Long-term psychosocial impact of venous thromboembolism: a qualitative study in the community","volume":"9","author":"R Hunter","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0316801.ref002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism.","volume":"8","author":"AA Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"pone.0316801.ref003","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1177\/0269216318757133","article-title":"Cancer patients\u2019 experiences living with venous thromboembolism: A systematic review and qualitative thematic synthesis","volume":"32","author":"NB Benelhaj","year":"2018","journal-title":"Palliat Med"},{"issue":"2","key":"pone.0316801.ref004","first-page":"219","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management.","volume":"117","author":"C Ay","year":"2017","journal-title":"ThrombHaemost"},{"issue":"4","key":"pone.0316801.ref005","first-page":"321","article-title":"The epidemiology of cancer-associated venous thromboembolism: An update.","volume":"45","author":"A Mahajan","year":"2019","journal-title":"SeminThrombHemost."},{"key":"pone.0316801.ref006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2018.05.028","article-title":"Guidelines\u2019 risk assessment recommendations for venous thromboembolism prophylaxis: A comparison and implementability appraisal","volume":"168","author":"MJ Moesker","year":"2018","journal-title":"Thromb Res"},{"issue":"10","key":"pone.0316801.ref007","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"AA Khorana","year":"2008","journal-title":"Blood"},{"issue":"9","key":"pone.0316801.ref008","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study","volume":"102","author":"N van Es","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"pone.0316801.ref009","doi-asserted-by":"crossref","DOI":"10.1186\/s13690-022-00820-7","article-title":"Physicians\u2019 perceptions and preferences for implementing venous thromboembolism (VTE) clinical practice guidelines: a qualitative study using the Theoretical Domains Framework (TDF).","volume":"80","author":"J Abboud","year":"2022","journal-title":"Arch Public Health."},{"issue":"7","key":"pone.0316801.ref010","first-page":"1211","article-title":"Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis","volume":"4","author":"KA Martin","year":"2020","journal-title":"Res PractThrombHaemost"},{"issue":"7","key":"pone.0316801.ref011","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1177\/10781552211035704","article-title":"Oncologists\u2019 attitudes towards prophylaxis of cancer associated venous thromboembolism: A prospective, descriptive study.","volume":"28","author":"EA Kandemir","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"pone.0316801.ref012","article-title":"Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study","volume":"12","author":"MJ Johnson","year":"2012","journal-title":"BMC Med Inform DecisMak."},{"issue":"5","key":"pone.0316801.ref013","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1200\/OP.21.00585","article-title":"The hardest weeks of my life: A qualitative study of experiences, practice changes, and emotional burden of New York City oncology physicians during the COVID-19 surge in 2020.","volume":"18","author":"KA Lynch","year":"2022","journal-title":"JCO Oncol Pract."},{"issue":"11","key":"pone.0316801.ref014","doi-asserted-by":"crossref","first-page":"e0166302","DOI":"10.1371\/journal.pone.0166302","article-title":"A qualitative study of medical oncologists\u2019 experiences of their profession and workforce sustainability.","volume":"11","author":"A Broom","year":"2016","journal-title":"PLoS One"},{"issue":"13","key":"pone.0316801.ref015","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.3390\/cancers15133311","article-title":"Assessing the needs of those who serve the Underserved: A qualitative study among US oncology clinicians","volume":"15","author":"MI Patel","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"2","key":"pone.0316801.ref016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology.","volume":"3","author":"V Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"pone.0316801.ref017","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.thromres.2018.01.018","article-title":"Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial","volume":"164","author":"M Kimpton","year":"2018","journal-title":"Thromb Res"},{"issue":"11","key":"pone.0316801.ref018","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1160\/TH17-03-0171","article-title":"Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: Rationale and design of the CASSINI trial","volume":"117","author":"AA Khorana","year":"2017","journal-title":"Thromb Haemost"},{"issue":"5","key":"pone.0316801.ref019","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.","volume":"38","author":"NS Key","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"pone.0316801.ref020","doi-asserted-by":"crossref","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"F Horsted","year":"2012","journal-title":"PLoS Med"},{"issue":"3","key":"pone.0316801.ref021","first-page":"8","article-title":"Assessment of adherence to National Comprehensive Cancer Network guideline recommended anticoagulant therapy in the management of patients with cancer-associated venous thromboembolic disease","volume":"2","author":"GH Naeemah","year":"2023","journal-title":"Maaen Journal for Medical Sciences"},{"issue":"0","key":"pone.0316801.ref022","doi-asserted-by":"crossref","first-page":"0","DOI":"10.33091\/amj.2024.147299.1607","article-title":"Venous Thromboembolism Risk Assessment Among Ambulatory Cancer Patients: Demographic Study and Doctor\u2019s Adherence to Guidelines.","volume":"0","author":"M Tariq","year":"2024","journal-title":"Al- Anbar Medical Journal"},{"issue":"15","key":"pone.0316801.ref023","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/archinte.164.15.1653","article-title":"Outcomes and cost of deep venous thrombosis among patients with cancer","volume":"164","author":"LS Elting","year":"2004","journal-title":"Arch Intern Med"},{"issue":"10","key":"pone.0316801.ref024","first-page":"1181","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology.","volume":"19","author":"MB Streiff","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"17","key":"pone.0316801.ref025","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"GH Lyman","year":"2013","journal-title":"J Clin Oncol"},{"key":"pone.0316801.ref026","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/jth.12725","article-title":"Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH","volume":"12","author":"AA Khorana","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"2","key":"pone.0316801.ref027","first-page":"45","article-title":"The use of D-dimer in exclusion of diagnosis of suspected Deep Vein Thrombosis.Iraqi J","volume":"4","author":"LJH Alqaisi","year":"2015","journal-title":"Hematology"},{"issue":"3","key":"pone.0316801.ref028","doi-asserted-by":"crossref","first-page":"139","DOI":"10.32007\/jfacmedbagdad.6431944","article-title":"D-dimer level and Wells score in women undergone Lymphadenectomy in Gynecological Cancer to Assess Risk of Deep Venous Thrombosis","volume":"64","author":"N Azzo","year":"2022","journal-title":"J Fac Med Baghdad"},{"issue":"5","key":"pone.0316801.ref029","first-page":"2369","article-title":"A comparison between wells\u2019 score and modified doppler ultrasound in the diagnosis of deep venous thrombosis of the lower limb","volume":"10","author":"M Khudder","year":"2019","journal-title":"Int J Pharm Sci Res"},{"issue":"10","key":"pone.0316801.ref030","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"AA Khorana","year":"2008","journal-title":"Blood"},{"issue":"01","key":"pone.0316801.ref031","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1055\/s-0041-1742227","article-title":"Physicians\u2019 views on utilization of an electronic health record\u2013embedded calculator to assess risk for venous thromboembolism among medical inpatients: A qualitative study.","volume":"06","author":"SR Moss","year":"2022","journal-title":"TH Open"},{"key":"pone.0316801.ref032","doi-asserted-by":"crossref","first-page":"2945978","DOI":"10.1155\/2021\/2945978","article-title":"Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty.","volume":"2021","author":"N \u00c7i\u00e7ek","year":"2021","journal-title":"Emerg Med Int."},{"key":"pone.0316801.ref033","first-page":"1","article-title":"Novel anticoagulants in the management of atrial fibrillation: A comprehensive comparative analysis.","volume":"71","author":"MM Jwaid","year":"2024","journal-title":"Farmatsiia (Sofia)."},{"issue":"1","key":"pone.0316801.ref034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.54133\/ajms.v6i1.437","article-title":"Assessment of Adherence and Self-Efficacy in a Sample of Iraqi Patients Receiving Warfarin or Direct Oral Anticoagulants.","volume":"6","author":"TM AL-Ameen","year":"2024","journal-title":"Al-Rafidain Journal of Medical Sciences"},{"issue":"3","key":"pone.0316801.ref035","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00520-020-05669-6","article-title":"Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist\u2019s impact on anticoagulant therapy","volume":"29","author":"EA Kandemir","year":"2021","journal-title":"Support Care Cancer"},{"issue":"4","key":"pone.0316801.ref036","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/10781552211004705","article-title":"Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre","volume":"27","author":"R. Pelletier","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"pone.0316801.ref037","doi-asserted-by":"crossref","first-page":"e000658","DOI":"10.1136\/bmjdrc-2019-000658","article-title":"Validity and reliability of anti-diabetic medication adherence scale among patients with diabetes in Baghdad, Iraq: a pilot study.","volume":"7","author":"EM Mikhael","year":"2019","journal-title":"BMJ Open Diabetes Res Care."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T18:27:09Z","timestamp":1736188029000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316801"}},"subtitle":[],"editor":[{"given":"Maher Abdelraheim","family":"Titi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316801","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}